





Through a window, Professor Johnny Mahlangu catches a brief glimpse of the beauty of Johannesburg's bushy landscape. He is heading from his office to a ward on the ninth floor of the Charlotte Maxeke Johannesburg Academic Hospital. The hospital is where Johnny, as head of the University of the Witwatersrand's School of Pathology, helps train aspiring undergraduate doctors and specialists.














In the mid-2010s, Johnny led a team of researchers from around the world to test whether a new type of haemophilia medicine could help blood to congeal better. The medications contained a molecule developed in Japan. It was tested on 152 patients in 45 countries. Like most other haemophilia treatments, it was injected.



In 2018, Johnny wrote an important report spelling out the research team's findings. It said: This works very well. As a bonus, patients are not injected so much. The treatment we currently use is injected three times a week directly and painfully into a vein somewhere on a patient's body. That adds up to 156 injections per year. This new treatment is only injected lightly under the skin twice a month. At only 24 needle pricks a year, that's a huge difference!

This was just one of many studies on blood of which Johnny has been a part. He's been fascinated by blood since his days as a science student at the University of Limpopo and the University of the Witwatersrand. By 1991, he had realised that this was clearly his life's calling.





'A haematologist. A doctor who specialises in blood and knows more about blood disease and blood tests than the average doctor,' he explained.

Johnny told her about diseases such as glandular fever, leukaemia and anaemia. 'Some people call leukaemia, blood cancer. Someone with anaemia is extremely tired because their iron levels are too low.'

